🎙️Thailand decriminalized cannabis in 2022, but a push to roll back the experiment is gaining steam.On today’s Big Take Asia: how the industry lost its way and what this weekend’s elections mean for its uncertain future ⤵️ ...

Core Insights - WM Technology, Inc. announced the appointment of Harry DeMott and Brent Cox to its Board of Directors, effective February 1, 2026, while Susan Echard will transition to a full-time Chief Financial Officer role on January 30, 2026 [1][2] Group 1: Board Appointments - Harry DeMott brings extensive experience in the cannabis and technology sectors, having co-founded Raptor Ventures and Outsider Labs, and previously served as CEO of Proper [2][3] - Brent Cox is a seasoned investment professional with a focus on growth and regulated businesses, currently serving as Founder and Managing Principal of Subtext Holdings [3] Group 2: Company Overview - WM Technology operates Weedmaps, a leading cannabis marketplace, and offers eCommerce and compliance software solutions for cannabis businesses [4][5] - The Weedmaps marketplace has become a premier destination for cannabis consumers, providing access to products, daily deals, and educational resources [5] Group 3: Company Mission - The company advocates for full U.S. legalization, social equity within the industry, and ongoing education about cannabis through partnerships and expert collaborations [6]

Thailand decriminalized cannabis in 2022, but a push to roll back the experiment is gaining steam. On today’s Big Take Asia: how the industry lost its way and what this weekend’s elections mean for its uncertain future. https://t.co/PJuUWOuVaX ...

Thailand decriminalized cannabis in 2022, but a push to roll back the experiment is gaining steam. On today’s Big Take Asia: how the industry lost its way and what this weekend’s elections mean for its uncertain future https://t.co/5fvyDqr8Z6 https://t.co/YdqQYRtgp8 ...

Core Viewpoint - Tilray Brands stock has experienced a significant decline, dropping over 68% from its peak in October, with a current price of $7.45, indicating a bearish trend but potential for a bullish reversal pattern to emerge [1] Group 1: Stock Performance - Tilray Brands stock price has fallen to its lowest level since December, with a notable drop from $15.75 in December to $7.45 currently [1] - The AdvisorShares Pure US Cannabis ETF has also seen a decline, falling from $7.25 in December to $4.10 [1] Group 2: Reasons for Decline - The stock's decline is attributed to the lack of progress in cannabis rescheduling, as Attorney General Pam Bondi has not taken steps to reschedule cannabis from Schedule 1 to Schedule 3, despite requests from former President Donald Trump [1] - The rescheduling process is expected to take months or years, and it is not anticipated to provide immediate benefits to companies like Tilray Brands, which face challenges in the banking sector [1] Group 3: Business Performance - Tilray Brands reported a 3% increase in revenue for the second quarter, totaling $217 million, but gross profit decreased from $61.2 million to $57.5 million [1] - Cannabis revenue remained stable at $65.7 million, while distribution revenue increased significantly from $67.6 million to $85.3 million, becoming the largest segment [1] - The beverage segment, however, saw a decline in revenue from $63 million to $50 million, and the wellness segment remained flat at $14.6 million [1] - The net loss improved slightly from $43.5 million to $41.8 million, with analysts projecting single-digit revenue growth moving forward [1] Group 4: Technical Analysis - The stock has moved below key technical levels, including the 78.6% Fibonacci Retracement level at $7.73 and the 50-day and 100-day Exponential Moving Averages [1] - Signs of a potential double-bottom pattern are emerging at $7, with a neckline at $15, suggesting a possible rebound in the coming weeks [1] - The next resistance level to monitor is the Major S&R Pivot Point at $12.5, with historical volatility indicating potential for a pullback following any rebound [1]

Core Insights - FLUENT Corp. has opened a new medical cannabis dispensary in Orlando, Florida, which is its second-largest location at over 5,000 square feet, featuring a drive-thru and self-ordering kiosks [1][4] - The dispensary is strategically located near major attractions such as SeaWorld and Universal Studios, enhancing its visibility and potential customer traffic [3][4] - The company operates 32 dispensaries in Florida and plans to expand to 37 locations nationwide by opening new dispensaries in Palm Bay, FL, and Houston, TX, in Q1 2026 [5] Company Overview - FLUENT is a national cannabis consumer packaged goods company focused on operational excellence in cultivation, production, distribution, and retail experience [5] - The company produces a variety of cannabis products under multiple brands, including MOODS, Knack, Wandr, Bag-O, and Hyer Kind, and operates in Florida, New York, and Texas [5] - FLUENT employs approximately 650 staff across 8 cultivation and manufacturing facilities and has a wholesale division named ENTOURAGE that services third-party retailers in New York [7]

Core Viewpoint - Village Farms International (VFF) is currently valued as a balanced agriculture company, but its financial performance is predominantly driven by its cannabis operations following the 2025 transaction that deconsolidated most of its produce business [1] Group 1: Company Overview - Village Farms International is involved in both vegetable and cannabis production, but the market perception is lagging behind its actual operational focus [1] - The deconsolidation in 2025 has shifted the company's earnings, margins, and operating leverage significantly towards cannabis, indicating a need for reevaluation of its market valuation [1]

Core Viewpoint - Organigram Global Inc., Canada's leading cannabis company by market share, is set to report its earnings results for the first quarter of fiscal 2026 on February 10, 2026, before the market opens [1]. Group 1 - The earnings report will cover the period ending December 31, 2025 [1]. - A conference call will be held to discuss the results, scheduled for February 10, 2026, at 8:00 am Eastern Time [1].

Core Viewpoint - Herbal Dispatch Inc. has amended the terms of its unsecured convertible debentures, extending the maturity date from January 31, 2026, to January 31, 2028, while maintaining other terms such as a 14% annual interest rate and a conversion price of CAD$0.06 [1][2]. Group 1: Amendment Details - The final amendment to the Convertible Debentures extends the maturity date to January 31, 2028, with the interest rate remaining at 14% per annum, a conversion price of CAD$0.06, and a threshold price of CAD$0.12 [2]. - The Company obtained an exemption from the Canadian Securities Exchange regarding certain requirements for convertible debenture amendments [3]. Group 2: Related Party Transactions - The amendment constitutes a "related party transaction" as both Mr. Malcolm and Mr. Dhaliwal are directors of the Company, requiring formal valuation and minority shareholder approval unless exemptions apply [4]. - The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements, asserting that the fair market value involved does not exceed 25% of the Company's market capitalization [5]. - The Board of Directors unanimously approved the Amendment, with Mr. Malcolm and Mr. Dhaliwal abstaining from the resolution [6]. Group 3: Company Overview - Herbal Dispatch Inc. is a leading operator of cannabis e-commerce platforms in Canada, providing quality medical and recreational products to consumers [8]. - The Company is actively expanding through exports to international markets, positioning itself for sustained growth and new revenue opportunities [8].

Core Thesis - Cronos Group Inc. is experiencing a bullish sentiment driven by renewed interest from the White House in rescheduling marijuana, leading to significant stock price increases and a positive outlook for the company's long-term positioning [3][4]. Company Overview - Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally [3]. Regulatory Changes - Plans to reclassify marijuana as a Schedule III substance could significantly reduce regulatory and tax burdens for the U.S. cannabis industry, which is expected to benefit Cronos Group [4][5]. - A Schedule III classification would allow cannabis operators to deduct normal operating expenses and access standard tax credits, enhancing cash flow and profitability potential for Cronos Group [5]. Strategic Positioning - Cronos Group is strategically backed by Altria Group and has existing U.S. exposure through PharmaCann, which operates 51 dispensaries across multiple states, positioning the company favorably ahead of potential federal legalization [5][6]. - Management views Canada as a pilot market, with the U.S. and Europe representing significant long-term growth opportunities as regulations evolve [6]. Market Performance - Since the initial bullish thesis, Cronos Group's stock has increased by approximately 67%, outperforming peers and cannabis ETFs, as investors anticipate improved fundamentals and market access [4]. Future Outlook - The potential rescheduling of marijuana could accelerate medical research and FDA-approved cannabis applications, further supporting the investment case for Cronos Group [7]. - The combination of improving regulatory momentum, tax normalization, strategic U.S. optionality, and disciplined long-term planning reinforces the attractiveness of Cronos Group as a long-term investment [8].